– http://www.reuters.com/healthNews
MADRID (Reuters) – It is too early to say whether combining Roche’s best-selling Avastin cancer drug with the company’s experimental immune-boosting medicine MPDL3280A gives a better outcome in fighting tumors.
Continue Reading On http://www.reuters.com/healthNews »
– http://www.reuters.com/healthNews
ST. PETERSBURG Fla. (Reuters) – Freshmen at Florida’s Lakewood High School lined up against gold and black gymnasium mats on Friday to have their height and weight measured, an assessment to launch a novel study on fighting teenage obesity with trendy new technology.
Continue Reading On http://www.reuters.com/healthNews »
MADRID, Sept 29 (Reuters) – Merck & Co’s new immune system drug Keytruda has produced encouraging results in early tests against bladder cancer, according to a company-sponsored study, prompting the firm to prepare a clinical trial later this year.
Continue Reading On http://www.reuters.com »
– http://www.reuters.com/healthNews
MADRID (Reuters) – A new breast cancer drug from Roche has shown “unprecedented” benefits in extending lives in a clinical trial and experts urged its widespread use for women with an aggressive form of the disease.
Continue Reading On http://www.reuters.com/healthNews »
* Says Bo Håkansson, Chairman of the Board , passed away on Sept. 28 following motocross accident Source text for Eikon: Further company coverage: (gdynia.newsroom@thomsonreuters.com; +48 58 698 3920)
Continue Reading On http://www.reuters.com »
– http://www.reuters.com/healthNews
NEW YORK (Reuters) – Walking may never become as trendy as CrossFit, as sexy as mud runs or as ego-boosting as Ironman races but for fitness experts who stress daily movement over workouts and an active lifestyle over weekends of warrior games, walking is a super star.
Continue Reading On http://www.reuters.com/healthNews »
No down payment medical, dental and healthcare provider practice financing here! + More News: Merck immunotherapy drug shows promise in bladder cancer + MORE 09/29/2014
No comments:
Post a Comment